cmg76
2021-12-22
Yes
BioRestorative Therapies shares surged 54.7% in premarket trading<blockquote>生物修复疗法股价在盘前交易中飙升 54.7%</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
3
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":691867601,"tweetId":"691867601","gmtCreate":1640168667367,"gmtModify":1640168987695,"author":{"id":3581589405041654,"idStr":"3581589405041654","authorId":3581589405041654,"authorIdStr":"3581589405041654","name":"cmg76","avatar":"https://static.tigerbbs.com/7bce68ec0cb45bf31e79e66a7fa376ad","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":25,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>Yes</p></body></html>","htmlText":"<html><head></head><body><p>Yes</p></body></html>","text":"Yes","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/691867601","repostId":1103276971,"repostType":4,"repost":{"id":"1103276971","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640165250,"share":"https://www.laohunote.com/m/news/1103276971?lang=zh_CN&edition=full","pubTime":"2021-12-22 17:27","market":"us","language":"en","title":"BioRestorative Therapies shares surged 54.7% in premarket trading<blockquote>生物修复疗法股价在盘前交易中飙升 54.7%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1103276971","media":"Tiger Newspress","summary":"BioRestorative Therapies shares surged 54.7% in premarket trading.BioRestorative Therapies, Inc., a ","content":"<p>BioRestorative Therapies shares surged 54.7% in premarket trading.<img src=\"https://static.tigerbbs.com/9f1c140edc65b98b443e358d9cda1655\" tg-width=\"719\" tg-height=\"576\" referrerpolicy=\"no-referrer\">BioRestorative Therapies, Inc., a life sciences company focused on adult stem cell-based therapies, announced it has entered into a Master Service Agreement with PRC Clinical, a contract research organization (CRO) specializing in clinical trial management to conduct BioRestorative’s Phase 2 clinical trial.</p><p><blockquote>BioRestorative Therapies 股价在盘前交易中飙升 54.7%。BioRestorative Therapies, Inc. 是一家专注于成人干细胞疗法的生命科学公司，该公司宣布已与专门从事临床试验管理的合同研究机构 (CRO) PRC Clinical 签订了一份主服务协议，以开展 BioRestorative 的 2 期临床试验。</blockquote></p><p> \"This is a significant milestone in our mission to develop cell-based therapeutics and to become a clinical stage company. We believe that PRC's renowned expertise in conducting clinicals trials and their use of innovative technology makes them an excellent CRO to partner with,\" said Lance Alstodt, Chief Executive Officer of BioRestorative Therapies. “This is the most meaningful step the Company has taken to initiate our clinical trial. We should now expect a host of developments pertaining to the advancement of our clinical trial, ultimately leading to the read out of our primary endpoints.”</p><p><blockquote>“这是我们开发细胞疗法和成为临床阶段公司使命中的一个重要里程碑。我们相信，PRC 在进行临床试验方面享有盛誉的专业知识以及他们对创新技术的使用使他们成为优秀的 CRO 合作伙伴，”Lance Alstodt 说道，BioRestorative Therapies 首席执行官。“这是公司为启动临床试验所采取的最有意义的一步。我们现在应该可以期待与临床试验进展相关的一系列进展，最终得出我们的主要终点。”</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioRestorative Therapies shares surged 54.7% in premarket trading<blockquote>生物修复疗法股价在盘前交易中飙升 54.7%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioRestorative Therapies shares surged 54.7% in premarket trading<blockquote>生物修复疗法股价在盘前交易中飙升 54.7%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-22 17:27</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>BioRestorative Therapies shares surged 54.7% in premarket trading.<img src=\"https://static.tigerbbs.com/9f1c140edc65b98b443e358d9cda1655\" tg-width=\"719\" tg-height=\"576\" referrerpolicy=\"no-referrer\">BioRestorative Therapies, Inc., a life sciences company focused on adult stem cell-based therapies, announced it has entered into a Master Service Agreement with PRC Clinical, a contract research organization (CRO) specializing in clinical trial management to conduct BioRestorative’s Phase 2 clinical trial.</p><p><blockquote>BioRestorative Therapies 股价在盘前交易中飙升 54.7%。BioRestorative Therapies, Inc. 是一家专注于成人干细胞疗法的生命科学公司，该公司宣布已与专门从事临床试验管理的合同研究机构 (CRO) PRC Clinical 签订了一份主服务协议，以开展 BioRestorative 的 2 期临床试验。</blockquote></p><p> \"This is a significant milestone in our mission to develop cell-based therapeutics and to become a clinical stage company. We believe that PRC's renowned expertise in conducting clinicals trials and their use of innovative technology makes them an excellent CRO to partner with,\" said Lance Alstodt, Chief Executive Officer of BioRestorative Therapies. “This is the most meaningful step the Company has taken to initiate our clinical trial. We should now expect a host of developments pertaining to the advancement of our clinical trial, ultimately leading to the read out of our primary endpoints.”</p><p><blockquote>“这是我们开发细胞疗法和成为临床阶段公司使命中的一个重要里程碑。我们相信，PRC 在进行临床试验方面享有盛誉的专业知识以及他们对创新技术的使用使他们成为优秀的 CRO 合作伙伴，”Lance Alstodt 说道，BioRestorative Therapies 首席执行官。“这是公司为启动临床试验所采取的最有意义的一步。我们现在应该可以期待与临床试验进展相关的一系列进展，最终得出我们的主要终点。”</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BRTX":"BioRestorative Therapies, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103276971","content_text":"BioRestorative Therapies shares surged 54.7% in premarket trading.BioRestorative Therapies, Inc., a life sciences company focused on adult stem cell-based therapies, announced it has entered into a Master Service Agreement with PRC Clinical, a contract research organization (CRO) specializing in clinical trial management to conduct BioRestorative’s Phase 2 clinical trial.\n\"This is a significant milestone in our mission to develop cell-based therapeutics and to become a clinical stage company. We believe that PRC's renowned expertise in conducting clinicals trials and their use of innovative technology makes them an excellent CRO to partner with,\" said Lance Alstodt, Chief Executive Officer of BioRestorative Therapies. “This is the most meaningful step the Company has taken to initiate our clinical trial. We should now expect a host of developments pertaining to the advancement of our clinical trial, ultimately leading to the read out of our primary endpoints.”","news_type":1,"symbols_score_info":{"BRTX":0.9}},"isVote":1,"tweetType":1,"viewCount":2743,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/691867601"}
精彩评论